FDA Clears Path for Depression Treatment GH001 to Enter Final Testing Phase

GH Research's (GHRS) experimental depression treatment GH001 gets FDA approval to proceed with clinical trials after lifting of clinical hold, targeting 2026 Phase 3 launch.